Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...

Zevra Therapeutics Inc (ZVRA) extends cash runway into 2027 while navigating revenue impacts and preparing for potential FDA ...

We recently compiled a list of the 10 Stocks with Biggest Upside Potential According to Hedge Funds. In this article, we are ...

Net Revenue: $172.8 million, representing 29% growth year-over-year. Net Income (Non-GAAP): $60.6 million, or $1.5 per ...